Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 209articles · 30d
- 1+ day agolatest article
- Aug 14, 2026earliest in window
- 94%with images
- 249avg words
- Medical 152
- Health & Wellness 141
- Health 103
- Science & Technology 48
- Business & Industrial 38
- Economy, Business & Finance 22
- Politics 20
- Politics2 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Breast cancer pill from AstraZeneca misses mark in pivotal trial
1+ day, 7+ hour ago (204+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...
Why two promising heart drugs flopped and what's next
2+ day, 20+ hour ago (222+ words) By Adam Feuerstein, Elaine Chen, and Allison DeAngelis On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did…...
Pharma wins a battle over the cost of wastewater treatment in Europe
1+ day, 16+ hour ago (180+ words) In a boost for the pharmaceutical industry, a European Union Advocate General recommended annulling part of a directive that requires drug and cosmetics manufacturers to finance at least 80% of the costs of wastewater treatment. The directive, which revised an earlier…...
Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
2+ day, 14+ hour ago (159+ words) The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines earlier this month. They could also have a chilling effect across the industry. Just before Labor Day, Novartis reported that its cardiac therapy, pelacarsen, failed in a…...
The gifts from pharma companies that keep on giving
2+ day, 21+ hour ago (218+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Pharmalittle: We're reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
4+ day, 1+ hour ago (167+ words) Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. FDA names acting heads of drug and vaccine…...
FDA approves AstraZeneca breast cancer drug
5+ day, 10+ min ago (148+ words) Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson…...
Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more
5+ day, 52+ min ago (369+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Inhibrx claims first win for long-sought immunotherapy target
5+ day, 2+ hour ago (136+ words) statnews.com Inhibrx said Tuesday that its experimental immunotherapy targeting a protein called OX40 showed responses in patients with head and neck cancer. But the most striking results were in a small subset of patients with HPV-positive tumors, which could significantly…...
Roivant lung disease drug hits mid-stage study goals
5+ day, 4+ hour ago (242+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the…...